[Present role of CT/PET in diffuse large B-cell lymphoma]

Area of Science:

• Oncology
• Medical Imaging

Background:

• Diffuse Large B-Cell Lymphoma (DLBCL) is the most common non-Hodgkin lymphoma.
• The utility of CT/PET imaging in initial DLBCL staging remains debated, rarely altering patient management.
• Recent consensus and trials highlight its role in evaluating end-of-treatment response.

Discussion:

• The role of CT/PET in assessing treatment response during therapy is gaining traction.
• This evaluation aims to implement "Risk Adapted Therapy" strategies.
• Further research is needed to fully integrate interim CT/PET into DLBCL management.

Key Insights:

• CT/PET imaging's primary value in DLBCL lies in post-treatment response assessment.
• Interim CT/PET is increasingly recognized for guiding risk-adapted therapeutic approaches.
• The controversial role in initial staging contrasts with its established utility in response evaluation.

Outlook:

• Future DLBCL treatment protocols may increasingly incorporate interim CT/PET for treatment adaptation.
• Standardization of interim CT/PET interpretation criteria is anticipated.
• This evolving role promises more personalized and effective lymphoma treatment.